Literature DB >> 16444583

Expression and characterization of wild-type TFPI and the [P151L]TFPI mutant in insect cells.

Elmar Thyzel1, Sabine Siegling, Thomas Brinkmann, Knut Kleesiek, Christian Götting.   

Abstract

Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type serine proteinase inhibitor that plays a central role in the extrinsic pathway of blood coagulation. In earlier studies we could identify the [P151L]TFPI mutant, and we could also demonstrate that heterozygous carriers of this mutant show a nine-fold increased risk for deep venous thrombosis (DVT). To express greater amounts of both proteins and to enable their characterization, we expressed wild-type TFPI as well as [P151L]TFPI in High Five insect cells with expression rates of up to 215 ng/ml for wild-type TFPI and 214 ng/ml for [P151L]TFPI. The specific inhibitory activities for the recombinant proteins were determined as 11.3 and 11.5 mU/ng, respectively. Both proteins were detected via Western blot analysis and ELISA. The recombinant proteins' inhibitory activities were characterized by a chromogenic assay and by the determination of a modified activated thromboplastin time (aPTT) in which both of them proved to be inhibitorily active. We also examined both recombinant proteins' binding properties to glycoproteins, glycosaminoglycans, lipoproteins and tissue factor. Our results show that we have developed an efficient model system for the recombinant expression of inhibitorily active wild-type TFPI as well as [P151L]TFPI in insect cells, and we were able to characterize both proteins' inhibitory properties by determination of their influence on the aPTT and also their binding properties. Although both recombinant proteins did not show a significant difference in their effect on the aPTT, their binding properties differed significantly between the wild type and mutant protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444583     DOI: 10.1007/s11010-006-2267-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  18 in total

1.  The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.

Authors:  K Kleesiek; M Schmidt; C Götting; B Schwenz; S Lange; G Müller-Berghaus; T Brinkmann; W Prohaska
Journal:  Thromb Haemost       Date:  1999-07       Impact factor: 5.249

2.  A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI.

Authors:  K Kleesiek; M Schmidt; C Götting; T Brinkmann; W Prohaska
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

3.  Characterization of the association of tissue factor pathway inhibitor with human placenta.

Authors:  Alan E Mast; Nayana Acharya; Mark J Malecha; Connie L Hall; Dennis J Dietzen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

4.  Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin.

Authors:  S Zucker; M H Cathey
Journal:  J Lab Clin Med       Date:  1969-02

Review 5.  Structure and biology of tissue factor pathway inhibitor.

Authors:  M S Bajaj; J J Birktoft; S A Steer; S P Bajaj
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

6.  Use of the activated partial thromboplastin time in the control of heparin administration.

Authors:  J G Lenaham; S Frye; G E Phillips
Journal:  Clin Chem       Date:  1966-05       Impact factor: 8.327

7.  Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects : impact of the V264M substitution on plasma levels of TFPI.

Authors:  D Moatti; P Seknadji; C Galand; O Poirier; F Fumeron; S Desprez; M Garbarz; D Dhermy; D Arveiler; A Evans; G Luc; J B Ruidavets; V Ollivier; J Hakim; M C Aumont; D de Prost
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-04       Impact factor: 8.311

8.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

Authors:  P M Sandset; U Abildgaard; M L Larsen
Journal:  Thromb Res       Date:  1988-06-15       Impact factor: 3.944

9.  Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.

Authors:  L V Rao; S I Rapaport
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

10.  Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin.

Authors:  E M Salonen; O Saksela; T Vartio; A Vaheri; L S Nielsen; J Zeuthen
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

View more
  1 in total

1.  In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.

Authors:  Jeong Pil Han; MinJeong Kim; Beom Seok Choi; Jeong Hyeon Lee; Geon Seong Lee; Michaela Jeong; Yeji Lee; Eun-Ah Kim; Hye-Kyung Oh; Nanyeong Go; Hyerim Lee; Kyu Jun Lee; Un Gi Kim; Jae Young Lee; Seokjoong Kim; Jun Chang; Hyukjin Lee; Dong Woo Song; Su Cheong Yeom
Journal:  Sci Adv       Date:  2022-01-21       Impact factor: 14.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.